

2026 Top 10 Drug List Report

Here are 10 growth-driver specialty medications we are closely tracking, educating our hospital and health system partners about and actively seeking for formulary additions to make available to patients as soon as possible.

Recent FDA approvals for 2025 included 46 novel (brand new) drugs, bringing new treatment options to patients and filling gaps in unmet medical needs. Of the novel drugs approved:

- 43% are classified as first-in-class, which means they introduce new mechanisms of action to treat specific medical conditions
- 50% are orphan drugs developed to treat rare diseases and often a small number of patients

Wegovy tablets

Manufactured by **Novo Nordisk**
Approved on 12.22.2025

Indication | **Weight management**

Attribute | Novel route of administration

Keytruda Qlex

Manufactured by **Merck**
Approved on 09.19.2025

Indication | **Multiple Cancers including melanoma, non-small cell lung cancer and gastric cancer among others.**

Attribute | Drugs with biomarker

Jascayd

Manufactured by **Boehringer Ingelheim**
Approved on 10.07.2025

Indication | **Idiopathic pulmonary fibrosis**

Attribute | Rare Disease/Orphan Drug; First-in-class approval

Yeztugo

Manufactured by **Gilead**
Approved on 06.18.2025

Indication | **Pre-exposure prophylaxis (PrEP)**

Attribute | Novel dosing regimen reduces adherence issues

Redempro

Manufactured by **Arrowhead**
Approved on 11.18.2025

Indication | **Familial chylomicronemia syndrome**

Attribute | Rare Disease/Orphan Drug

Anzupgo

Manufactured by **LEO Pharma**
Approved on 07.23.2025

Indication | **Chronic hand eczema**

Attribute | Unique to this specific indication

Rhapsido

Manufactured by **Novartis**
Approved on 09.30.2025

Indication | **Chronic spontaneous urticaria**

Attribute | First-in-class approval

Avmapki Fakzynja Co-Pack

Manufactured by **Verastem**
Approved on 05.08.2025

Indication | **KRAS-mutated, recurrent low-grade serous ovarian cancer**

Attribute | First-in-class approval; Drugs with biomarker

Komzifti

Manufactured by **Kura Oncology**
Approved on 11.13.2025

Indication | **Relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation**

Attribute | Drugs with biomarker

Inluriyo

Manufactured by **Eli Lilly**
Approved on 09.25.2025

Indication | **ER-positive, human epidermal growth factor 2-negative (HER2-), ESRI-mutated advanced or metastatic breast cancer**

Attribute | Drugs with biomarker

About Clearway Health

Clearway Health's specialty pharmacy services create sustainable assets and build lasting legacies for hospitals and health systems, providing a service that every patient deserves. Our team began at Boston Medical Center Health System, improving access to care and managing the complex medication needs of vulnerable patient populations and now partners with hospitals across the country.

With our exclusive focus on transforming specialty pharmacy, we have proven expertise and driven results by expanding our partner clients' access to vital new medications approved by the U.S. Food and Drug Administration (FDA). This has a waterfall effect of expanding patient access to the latest and most innovative medications, improving their health outcomes and the overall vitality of the organizations and communities we serve.

Our specialty pharmacy team stays current on medications that are recently approved or newly available in the market. We work with clinic providers and staff to educate them on emerging therapies as well as provide detailed patient education. In areas like oncology, dermatology and cardiology, as well as continuously evolving therapies for weight management, pre-exposure prophylaxis (PrEP) and pulmonary fibrosis, Clearway Health staff are uniquely positioned and trained to support novel therapies and associated patient needs. We help our clients understand the landscape and navigate how to add these medications to their formularies so their patients can see the benefits faster.

Ready to transform your specialty pharmacy program?

A specialty pharmacy program is a transformative asset for any hospital or health system. For more information on specialty pharmacy programs, including the impact of new and upcoming medications and unlocking payer and PBM networks, visit www.clearwayhealth.com/connect